Mucormycosis in Deferoxamine-Treated Patients on Dialysis
Authors: Judith H. Veis, Robert Contiguglia, Melvyn Klein, Jeffrey Mishell, Allen C. Alfrey, Joseph I. Shapiro
Journal: Annals of Internal Medicine (1987)

Letters and Corrections1 August 1987Mucormycosis in Deferoxamine-Treated Patients on DialysisJUDITH H. VEIS, M.D., ROBERT CONTIGUGLIA, M.D., MELVYN KLEIN, M.D., JEFFREY MISHELL, M.D., ALLEN C. ALFREY, M.D., JOSEPH I. SHAPIRO, M.D.JUDITH H. VEIS, M.D.Search for more papers by this author, ROBERT CONTIGUGLIA, M.D.Search for more papers by this author, MELVYN KLEIN, M.D.Search for more papers by this author, JEFFREY MISHELL, M.D.Search for more papers by this author, ALLEN C. ALFREY, M.D.Search for more papers by this author, JOSEPH I. SHAPIRO, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-107-2-258_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Deferoxamine has been increasingly used to treat iron and aluminum overload in uremic patients on dialysis. Because of the lack of renal function, the half-life of deferoxamine and its chelates, feroxamine and aluminoxamine, is markedly prolonged in this population (1). Although this action improves the effectiveness of chelation, toxicity could also be increased.We recently saw fatal fungal infections in two nondiabetic patients among our patients on chronic dialysis who were receiving deferoxamine therapy. These patients had received deferoxamine for aluminum-associated bone disease for 4 months and 1 year, respectively. They were receiving a dose of 2...References1. FOSBURGHAKIMSCHULMAN MRG. Pharmokinetics (K) of desferoxamine (D) during treatment of transfusional iron overload (IO) in chronic hemodialysis (HD) patients [Abstract]. Am Soc Nephrol. 1983;16:46A. Google Scholar2. LEHRERHOWARDSYPHERDEDWARDSSEGALWINSTON RDPJGD. Mucormycosis. Ann Intern Med. 1980;93:93-108. LinkGoogle Scholar3. GLUSKINSOLOMONGOLDCORRADOBERGER MMBMJ. Mucormycotic slough of nasal floor and palate in the anephric patient. JADA. 1979;98:224-7. MedlineGoogle Scholar4. ROBINS-BROWNEPRPIC RJ. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica. Infect Immun. 1985;47:774-9. CrossrefMedlineGoogle Scholar5. WEINBERG E. Iron and infection. Microbiol Rev. 1978;42:45-66. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: JUDITH H. VEIS, M.D.; ROBERT CONTIGUGLIA, M.D.; MELVYN KLEIN, M.D.; JEFFREY MISHELL, M.D.; ALLEN C. ALFREY, M.D.; JOSEPH I. SHAPIRO, M.D.Affiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAcute myocardial infarction caused by coronary mucormycotic embolismDeferoxamineAdverse immunological effects of drugs other than anticance drugs and drugs used in immunologyMucormycosis: an emerging disease?DeferoxamineAluminum Toxicity Following IV Use of Oral Methadone SolutionA fatal case of disseminated zygomycosis associated with the use of blood glucose self-monitoring equipmentBone metabolism and disease in chronic kidney diseaseCase 9-2002Peptide siderophoresSurvival factors in rhino-orbital-cerebral mucormycosisDeferoxamine Therapy and Mucormycosis in Dialysis Patients: Report of an International RegistryFatal Mucormycosis Therapy Associated with DeferoxamineIntestinal Mucormycosis in a Hemodialysis Patient Treated with DesferrioxamineEffects of iron and desferrioxamine on Rhizopus infectionFailure of Deferoxamine to Improve Iron Overload in Chronic Hemodialysis PatientsDeferoxamine therapy of aluminum toxicity in dialysis patientsBacterial iron enhances oxygen radical-mediated killing of Staphylococcus aureus by phagocytesMucormycosis: association with deferoxamine therapyPeritoneal Mucormycosis in a Patient Receiving Continuous Ambulatory Peritoneal DialysisThe Role of Aluminum in the Pathogenesis of Anemia in an Outpatient Hemodialysis PopulationDialysis DementiaMetal antagonistsMucormycosis Infection in Dialysis PatientsJOHAN R. BOELAERT, M.D., PHILIPPE L. VERGAUWE, M.D., JOZEF M. VANDEPITTE, M.D.Organ and Metabolic Complications: Trace Elements 1 August 1987Volume 107, Issue 2Page: 258-258KeywordsBoneHalf lifeMedical dialysisToxicity ePublished: 1 December 2008 Issue Published: 1 August 1987 PDF downloadLoading ...